AA Financial Advisors LLC Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AA Financial Advisors LLC lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.1% in the 4th quarter, Holdings Channel reports. The firm owned 448 shares of the biopharmaceutical company’s stock after acquiring an additional 62 shares during the period. AA Financial Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $319,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. Mizuho Securities USA LLC raised its holdings in shares of Regeneron Pharmaceuticals by 625.5% during the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after purchasing an additional 51,162 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after acquiring an additional 2,828 shares during the period. Simplify Asset Management Inc. boosted its position in Regeneron Pharmaceuticals by 50.8% in the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after purchasing an additional 3,231 shares during the last quarter. Catalytic Wealth RIA LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $1,334,000. Finally, Daiwa Securities Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 12.3% during the 3rd quarter. Daiwa Securities Group Inc. now owns 20,384 shares of the biopharmaceutical company’s stock valued at $21,428,000 after purchasing an additional 2,234 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $683.08 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $666.25 and a 52-week high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm’s fifty day moving average is $723.36 and its 200 day moving average is $928.61. The company has a market cap of $75.06 billion, a price-to-earnings ratio of 16.90, a PEG ratio of 1.62 and a beta of 0.10.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of research reports. Evercore ISI reduced their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Piper Sandler cut their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a report on Monday. Oppenheimer decreased their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Citigroup cut their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research note on Tuesday. Finally, Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,004.57.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.